NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP
YD Bio Limited YDES
3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$596,817
▲ 16.9% vs FY2024
EPS · FY25
$-0.12
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-445.1%
Net margin · FY25
-1392.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 596,817.00
Revenue, FY2025 · full 3-year series below
Revenue
Net income
The company lost 1393 cents on every revenue dollar this year.
Per share
USD -0.12
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-445.1%
Return on equity, FY2025
ROE
Operating margin-883.3%
Net margin-1392.6%
Return on assets-80.5%
Each USD of equity lost 445 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.07B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 13.8M
total assets, end of FY2025
Total assetsUSD 13.8M
EquityUSD -2.9M
CashUSD 6.0M
Gross debtUSD 6,764.00
Net debtUSD -6.0M
Current ratio5.88×
The company holds more cash than debt.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
0.0
EPS, diluted $
−0.12
−0.02
0.00
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−445.1
−42.7
59.0
Shares out B
0.07
0.06
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
9 of 9
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed